Bispecific antibodies retargeting T cells to tumor cells have become a well-known tool for cancer therapy. A prominent example of a bispecific antigen is blinatumomab (CD19/CD3), whose development spurred the diverse forms of engineering in bispecific antigens. However, several challenges are faced as a part of tumor escape and resistance mechanisms. These include tumor heterogeneity and antigen loss.
Trispecific antibodies The current generation of trispecific antibodies, which targets two different tumor-associated antigens, is expected to overcome the challenges by improving tumor selectivity and specificity. But, the design of trispecific antibodies forming immunological synapses is however challenging due to the individual differences in target size and epitope position. As a result, there is no “one best option” and individual solutions are needed. In a recent study by Zhao et…
